Healthtech startup, DrugStoc has raised USD 4.4 million in Series A funding to expand access to quality medicines while providing sustainable supply chain financing for healthcare providers in Sub-Saharan Africa. The funding round is led by Africa HealthCare Master Fund (AAIC), and other investors include Chicago-based venture firm Vested World and the German Development Bank (DEG).
Nobuhiko Ichimiya, Director at AAIC, stated that, “We are very excited to be part of the DrugStoc journey. The pharmaceutical market in Africa has enormous growth potential and we are glad to back a company well positioned to be a key player in the sector’s growth in sub-saharan Africa.”
Launched in 2017, DrugStoc is a cloud-based platform that provides healthcare providers with the interface for easy access to pharmaceuticals and healthcare products. It ensures that patients get quality medicines at affordable prices. It boasts superior quality control systems with International Organization for Standardization (ISO) certification on Good Distribution Practice.
Having grown over the last three years with an almost 1500% increase in monthly sales since January 2018, 14 million people currently have access to genuine healthcare products through hospitals and pharmacies covered by DrugStoc. With this funding round, the company will grow coverage to about 100 million people. It plans to achieve this by expanding its supply chain infrastructure both digitally and physically. Digital expansion will see DrugStoc build out its tech solutions to boost access and accommodate more partners as it extends coverage beyond Lagos. DrugStoc will also invest in quality cold chain infrastructure to enhance safe distribution of perishable products; and build on its partnerships with financial institutions such as Sterling Bank, to increase access to sustainable supply chain financing.
The company, founded by two seasoned professionals in the health sector, Chibuzo Opara and Adham Yehia, has powered over nine million prescriptions and projects 12 million by the end of 2021. Chibuzo Opara, DrugStoc’s co-founder and CEO, said: “Fragile and resource-challenged healthcare systems require a radically transformative set of market-based strategies to expand access to healthcare. The DrugStoc way re-engineers the value chain digitally, improving and expanding access to healthcare at the same time.”
It is predicted that Africa’s pharmaceutical industry will be worth $56 billion to $70 billion by 2030, from just $5.5 billion in 2007. However, the broken supply chain and chaotic distribution channels on the continent still pose a significant challenge. It affects the delivery of quality medicines, affordability of pharmaceuticals, and efficient healthcare delivery for health workers. Innovation to solve supply chain challenges is a key opportunity in this growing market.
According to Liam O’Connor, who is also among a group of individual Silicon Valley investors, “DrugStoc has demonstrated impressive growth and the ability to improve healthcare providers’ access to pharmaceuticals in Nigeria. I am excited to support DrugStoc’s innovative work building a reliable, resilient, and high-quality pharmaceutical supply chain across Africa. I am confident that DrugStoc will succeed in making a critical healthcare difference that will help save lives.”
In 2016, DrugStoc was incubated under Stanford’s Institute for Innovation in Developing Economies; and in 2019 made the shortlist as one of ten finalists for the Africa Netpreneur Prize Initiative, Jack Ma’s flagship entrepreneur program in Africa. It also won the award for the Technology Enabled Distributor of the year, at the Nigeria Health Excellence Award in 2019 and 2021.
The healthtech startup will now double down on its vision to change the way healthcare providers interface with the pharmaceutical market and revolutionize sub-Saharan Africa’s access to quality pharmaceuticals.
